Investorideas.com Security and Defense Conference adds New Speakers and Media Partners and Presenters

New York, N.Y. - January 22, 2014 (www.investorideas.com newswire) Investorideas.com, an investor research and news portal covering leading sectors including technology and defense, announces new speakers and media partners for its upcoming Security and Defense Conference to be held in New York on March 11, 2014. Added to the growing list of speakers and presenters is Kris Tuttle Director of Research for SoundView Technology Group.

Media partners include SecuritySolutionsWatch.com, a breaking News site covering new security solutions and business trends, SecurityStockWatch.com for investors following the sector, www.Wallstreetcalendar.com , informing the institutional investment community, Australian Security Magazine ( http://www.australiansecuritymagazine.com.au/ ) Global Security Finance (www.globalsecurityfinance.com), an online daily news and data service covering the physical, cyber and identity security and defense sectors, and Hedge Connection ( https://www.hedgeconnection.com ), an interactive, web-based marketing tool available to hedge funds and investors.
Current speakers include Marty Martin, CEO of Crane & Crane Consulting, who also has a background with the CIA, NSA, and the U.S. Army, Scott Greiper, President and Founding Partner of Secure Strategy Group, Scott Sacknoff, President of Spade Defense Index (NYSE: ^DXS) .
The theme of the conference is game changing technologies, changing the face and the future of security.
“According to The Washington Post, biometrics might be the one to watch. In much the same way that 3D printing was an engineering resource that had remained under the radar for some time, biometric technology is one that has gathered more traction over the last few months. "
Source: http://why.knovel.com/all-engineering-news/2908-biometric-technology-could-be-one-to-watch-in-2014.html
Investorideas.com Security and Defense Conference:
Game Changing Technologies: The Face and Future of Security
Tuesday, March 11, 2014
The New York Hilton Midtown and Online at Scribblelive.com, a unique content and syndication platform
Learn more about the conference and register:
http://www.investorideas.com/Conference
On March 11, 2014 Hear Industry Analysts, Industry Experts and Management of Leading Companies Discuss How Technology is Transforming the Future of Security

• Over 15 Presenting Companies and 500 expected attendees
• Commentary From Top Industry Experts, Government Officials and Analysts, Live and Online
• Real Time Live Syndication Platform
• Social Media Interaction
• Extensive Media Coverage

Authentication Technology, Biometrics, Biodefense, Drones, Nanotechnology & Technology is evolving faster than we think!
This one day event (both live and online) will give investors and industry participants insight as to where to invest and the key trends to pay attention to.
Live conference attendance is free for industry experts, investors, media and service providers.
Presenting Speakers:
Kris Tuttle, SoundView Technology Group
Kris Tuttle is the Director of Research for SoundView Technology Group which focuses on researching and analyzing emerging public companies in new technology areas. Kris has 35 years of active participation in computing technologies including as an early designer and programmer of microcomputers, a researcher building artificial intelligence applications at Carnegie Mellon University and a career at IBM applying a range of advanced technologies to the most challenging business applications faced by Fortune 500 companies.
Starting in 1992 he has been applying this background to technology stock investing. After the original SoundView was acquired, ultimately by UBS and Charles Schwab, he founded his own firm in 2005 and renamed it SoundView after re-acquiring the SoundView trademarks. Today the firm is focused on advisory services, research and developing more internet-based research and information services.
Kris has a BS in Applied Math/Computer Science from Carnegie Mellon University and an MBA in Finance from the NYU Stern School of Business.
Marty Martin, CEO, Crane & Crane Consulting
Marty Martin has an accomplished career which includes service with the CIA, NSA, and the U.S. Army. He has developed invaluable insight, managerial experience, and relationships across the U.S. Government and many foreign governments and intelligence services at the highest levels. He is the CEO of Crane & Crane Consulting, LLC where he leads the firm's expansion and growth. He previously served as a Senior Executive for the International Oil Trading Company (IOTC), a multi-billion dollar enterprise with activities in Iraq, Jordan, Libya, Russia and the Caribbean. He also played a central role in HBO's Manhunt, a 2013 Emmy awarding winning documentary. Mr. Martin's experience includes over 29 years of U.S. Government service including U.S. Special Forces, the National Security Agency, and the CIA, culminating in several years as a member of the CIA's Senior Intelligence Service. From 2004 through 2007 he served as Chief of Station in a strategic country in the Middle East in one of the most senior assignments in the Near East Division. He managed a multi-million dollar budget, strategic programs, personnel, and families in high threat environment. His experience includes representing the CIA at the highest levels in foreign countries, the U.S. Executive Branch, the U.S. Congress, U.S. Military, on all intelligence and policy matters concerning the agency's operations. In 2002 he was selected by the Director of Central Intelligence as the senior executive and operational manager to lead the Agency's global effort to neutralize Al-Qaida. In that role, he interacted at the highest levels of the U.S Government, including the White House, FBI, Homeland Security, NSA, Congress, and various branches of the U.S. Military, on a daily basis. During this specific period the lion's share of the perpetrators of 9/11 were nullified.
Scott Greiper, President and Founding Partner of Secure Strategy Group
Mr. Greiper is the President and Founding Partner of Secure Strategy Group. He has had a distinguished 15-year career in the security and defense technology sectors as both a research analyst and investment banker, and is known as a thought leader in the industry. Before forming Secure Strategy Group, he was a Managing Director at Legend Merchant Group and Head of the firm's Convergent Security Group, which provided capital, strategic advisory and M&A services to growth companies in the security and defense technology markets. Previously, Mr. Greiper was a Principal and Senior Analyst at C. E. Unterberg, Towbin, where he covered public companies in the Global Security industry and was consistently ranked as one of the top analysts in the sector. He has worked with a range of industry leaders and is a frequent guest speaker and moderator at conferences and seminars across the country. Mr. Greiper attended the Executive MBA program at Columbia University and holds a B. A. in Economics from The University of Chicago. He is a member of the FBI InfraGard program, BENS (Business Executives for National Security), ASIS (American Society for Industrial Security) and NYSSA (New York Society for Security Analysts).
Scott Sacknoff, President, The Spade Defense Index
Mr. Scott Sacknoff is the Index Manager of the SPADE Defense Index (NYSE: ^DXS), the underlying index for the Powershares Aerospace & Defense ETF (NYSE: PPA). The SPADE® Defense Index (NYSE: ^DXS) is a modified capitalization-weighted index comprised of publicly traded companies that benchmarks the performance of companies involved with defense, homeland security, and space. The Index is composed of more than 50 firms with representative business activities including: naval vessels, military aircraft, missiles and munitions, battlespace awareness, C4ISR, network centric warfare, homeland security including border security and biometric and screening systems, and space systems. Index values are distributed by the NYSEarca under the ticker 'DXS'. The Powershares Aerospace & Defense Portfolio ETF, designed to track the SPADE Defense Index, trades under the ticker 'PPA'. Historical data for the Index is available from 30 December 1997. The ETF was launched on 26 October 2005 and is highly liquid.
Presenting Companies: Visit the conference page to learn more and sign up:
http://www.investorideas.com/Conference
Media:
SecuritySolutionsWatch.com features thought leadership interviews about security solutions. As the #1 Google site for Physical Security Solutions, Secure ID Solutions and Security Stocks our channel delivers an excellent branding and lead generation opportunity for new business + greater investor awareness.
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Sign up for our free news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and use our online stock directories to research stocks - waters stocks, renewable energy, tech, mobile, mining stocks and more… http://www.investorideas.com/membership
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.aspBC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Disclosure: NXTD and Tekcapital are clients of Investorideas.com .http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Presenting Companies Contact info:
Cali V cvanzant@investorideas.com 800. 665. 0411
Sponsorship info:
Eric Salvarezza esalvarezza@investorideas.com 631. 664. 1311
Media Partners:
Dawn V dvanzant@investorideas.com 800. 665. 0411
800-665-0411 - Source: www.Investorideas.com

Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Biotech News Alert: SUNSHINE BIOPHARMA (OTCQB: SBFM) EXPANDS DRUG PIPELINE TARGETING PANCREATIC CANCER AS SECOND INDICATION FOR CLINICAL TRIALS OF Adva-27a COMPOUND

Montreal, Quebec, Canada - January 22, 2014 (Investorideas.com Biotech Newswire) Biopharma alert: Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, reports that it is targeting pancreatic cancer as a second indication for Adva-27a, the Company’s flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.

Full news: http://www.investorideas.com/CO/SBFM/news/2014/01211.asp
January 21 st Close : $0.20 Up 0.03(14.29%)
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
About Sunshine Biopharma Inc.
Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which is currently targeted for multidrug resistant cancer.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.aspBC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Biometric Stock Alert: Mobile Biometric Company NXT-ID, Inc. (OTCQB: NXTD) to Team With the John F. Welch College of Business at Sacred Heart University

SHELTON, CT - January 21, 2014 (Investorideas.com Newswire) NXT-ID (OTCQB: NXTD), a biometrics company focused on the growing m-commerce market, announces it will be doing a joint project with students at the John F. Welch College of Business at Sacred Heart University in Fairfield, CT to assist with the marketing roll out of its next generation smart wallet, the Wocket™.

The Wocket™ is a new biometrically secure smart wallet designed to replace the traditional wallet and the number of cards consumers carry. Its dynamically programmable magnetic stripe, NXTCard can replace more than 100 cards and can include medical records, ID, coupons etc. that are currently kept in a wallet, with one single secure card.
In the initial phase of the project, students will research the market, the competition, and consumer trends related to the Wocket. The second part of the project will be primary research (surveys and focus groups) on the product, its features, possible marketing positioning and pricing and the final phase will be live on campus testing.
"We are delighted to be announcing this collaboration with the John F. Welch College of Business," said Mr. Gino Pereira, CEO of NXT-ID, Inc. "It is particularly relevant as one of our initial target group of customers for the Wocket are college students and campuses where there is a unique combination of open loop and closed loop payment systems combined with a particular need for security with access control to buildings."
"We are looking forward to working with Nxt-ID and their innovative technology," said Kwamie Dunbar, assistant professor of Finance at the John F. Welch College of Business. "This gives our students the type of real life hands on experience that the College prides itself on."
On January 25, 2006, Jack Welch, the former Chairman and CEO of General Electric, gave an endowment and his name to Sacred Heart University's College of Business, which is now known as the John F. Welch College of Business.
About the John F. Welsh College of Business
The John F. Welch College of Business at Sacred Heart emphasizes core business skills and knowledge, communications skills, and ethics. We stress hands on learning, understanding of the global marketplace, and state-of-the-art technology. The College enrolls over 950 students in undergraduate and graduate degree programs and the faculty consists of more than 40 professors, who are recognized scholars and experienced practitioners in the business world.
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™, a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/
NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013 :Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous services
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Biotech News Alert: Sunshine Biopharma (OTCQB: SBFM) Targets Pancreatic Cancer as Second Indication for Clinical Trials of Adva-27a Compound

MONTREAL, QC - January 21, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma Inc. ( OTCQB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is now targeting pancreatic cancer as a second indication for Adva-27a, the Company's flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.

"As we work towards completing the process of re-domiciling the Company to Canada and conducting the requisite IND-enabling toxicology studies of Adva-27a, we are now proceeding with additional research centered on pancreatic cancer as a second indication," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "Pancreatic cancer represents an area of tremendous unmet medical need and significant market opportunity. Our research to date indicates that Adva-27a has the potential to become a new therapy option for patients suffering this deadly form of cancer."
About Pancreatic Cancer
Pancreatic cancer has an extremely poor prognosis. Most pancreatic cancer patients will die within one year of diagnosis. Cancer of the pancreas is the fourth most common cause of cancer-related deaths in the United States. According to the American Cancer Society, an estimated 45,220 new cases of pancreatic cancer will be diagnosed in the U.S. in 2013. Approximately 95% of pancreatic tumors are of the adenocarcinoma type, arising within the exocrine component of the pancreas where various digestive enzymes are produced. The remaining 5% arise from the islet cells and are classified as neuroendocrine tumors. The islet cells produce important hormones such as insulin, which regulates the sugar levels in the blood. Both types are very aggressive and respond poorly to standard chemotherapy drugs. In contrast to the downward trend in death rates for most major cancer types, death rates due to pancreatic cancer have been slowly increasing in the U.S. over the past decade. This, together with the lack effective therapy, underscores the need for major new drug development efforts to reverse these trends.
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
About Sunshine Biopharma Inc.
Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which is currently targeted for multidrug resistant cancer.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

TSX Biotech Stock: Q&A Interview with CEO of Quest PharmaTech (TSX.V: QPT)

New York NY - Point Roberts WA - January 21, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues an exclusive interview with Dr. Madi R. Madiyalakan, Ph.D., Chief Executive Officer of Quest PharmaTech Inc. (TSX.V: QPT). Dr. Madiyalakan shares insight into the Company’s pipeline of oncology products. The Company takes a unique approach to cancer treatment that capitalizes on the recent major advances in the understanding of immune physiology and developing proprietary next generation cancer immunotherapy treatments using select antibodies, adjuvants and photosensitizers.

Interview:
Q: Investorideas.com
For readers unfamiliar with your company, can you give a brief introduction on your background in the biotech space and the formation of Quest PharmaTech?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
I have been involved in the Biotech industry for over 27 years, first as a scientist at Biomira Inc (now known as Oncothyreon) and then as a founding executive team member of several biotech companies including, AltaRex Corp., CanBiocin Inc. and SonoLight Pharmaceuticals Corp. My relationship with Quest began when Quest PharmaTech acquired SonoLight Pharmaceuticals in 2001. That acquisition provided a path forward for technology I had invented and championed ([Dr. Madiyalakan holds 10 primary U.S. patents and eight pending patents]). I have been instrumental in raising more than $200 million through private placement and public offerings for those companies. I specialize in advancing novel technologies with great therapeutic potential in areas of unmet medical need.
Quest was started as a research and development company in 1998 and was listed on the TSX Venture Exchange in 1999. I have been CEO of the Company since 2006.
Q: Investorideas.com
Can you briefly describe the current product portfolio and the primary oncology focus for each?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Our technology is focused on the immunotherapy of cancer. We utilize tumor directed monoclonal antibodies to activate the specific immunity; however we recognize that successful therapy requires orchestrated combination with chemotherapy, photodynamic therapy and select additional immune modulators or adjuvants. Our lead product, Oregovomab, which is currently completing a phase II clinical trial in both Italy and the U.S., is used in combination with standard chemotherapy in ovarian cancer patients. It is also being tested in combination with other immunotherapeutic agents for use in treating pancreatic cancer patients. Our pipeline also includes proprietary antibodies against other cancer markers, most notably MUC1, PSA and HER2. We expect to advance our MUC1 targeting antibody into the clinic in the coming year. MUC1 expressing cancers include many commonly occurring solid cancers such as breast, pancreatic and lung cancers.
We are also very excited about our new pipeline of therapeutic IgE antibodies, which we recently acquired from Advanced Immune Therapeutics, Inc. and for which we obtained license rights from UCLA and Stanford University. In addition to their immunotherapeutic potential, these molecules also have the potential to act in the tumor micro-environment to augment the effectiveness of chemotherapy. We truly believe that the IgE technology will be a breakthrough for the treatment of cancer.
Q: Investorideas.com
Can you discuss the current status of your flagship product OREGOVOMAB and its applications in immune therapy?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Quest's proprietary approach uses antibodies to modulate and enhance specific immunity to the target tumor antigen and associated tumor. Recent insights into the ability of cytotoxic therapy to enhance immunity, and the development of novel adjuvant approaches, suggests that a simple and artful approach using a combination of components for specific cancer immunotherapy can change the clinical course of cancer. We are using our lead product Oregovomab as an example to demonstrate the proof of concept for the combinatorial immunotherapeutic approach and trying to identify ideal combinations by conducting three different clinical trials. The most advanced of these is an 80 patient phase II clinical trial in advanced ovarian cancer patients that is being conducted in 13 clinical centers in Italy and the U.S. We hope the results from this trial will confirm the findings in an earlier study that shows combining chemotherapy with Oregovomab leads to the generation of specific anti-cancer T-cells and the potential for clinical benefits. We are also conducting another clinical trial in the U.S. using Oregovomab in combination with another chemotherapeutic agent, Gemcitabine, together with radiation therapy for treating pancreatic cancer. The trial will help us to expand the market opportunities for Oregovomab to other CA125 expressing cancers as well as to evaluate immunotherapy in combination with chemo radiotherapy. We are also looking at the addition of an immunoadjuvant, Hiltonol, a TLR3 agonist, which we have licensed from a U.S based company, Oncovir, to further augment the immune response. The completion of these 3 clinical trials will provide us with the roadmap for commercialization of this product. To summarize, Quest's approach has created an opportunity to mobilize immunity, better, more precisely and for less cost than other methods that are in development, and, or, recently approved.
Q: Investorideas.com
Can you give us some background on the key members of your team and the scientific board and the expertise they bring to the company?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Working with me on themanagement team, I have Thomas Woo, Vice President of Product Development since 2002. Thomas honed his drug development skills at Biomira, AltaRex and Cytovax. My CFO, Pierre Vermette, comes with extensive experience gained at the Alberta Securities Commission and has been with the Company since 2003.
On theBoard of Directors, I have Lorne Meikle, our Chairman, Ian McConnan, our Audit Committee Chair and Paul Van Damme, our Corporate Governance Chair.
Mr. Meikle has an extensive background in the life sciences area, Mr. McConnan is a former partner of several public accounting firms, and Mr. Van Damme has acted in the CFO role for a number of public and private companies.
On the Company's Scientific Advisory Board, I have internationally known scientists who occupy important positions in various institutions around the world. Dr. Samuel Abraham, Ph.D., is the Vice President of Research with the British Columbia Cancer Agency. Professor Ki-Jun Hwang is a well respected medicinal chemist at Chonbuk University in South Korea. One of the clinicians, Dr. Ronald Moore, who is developing a unique treatment for prostate cancer at the Cross Cancer Institute in Canada, is also one of our scientific advisory board members. Dr. Moore, along with Dr. Gerald Miller in Australia, provide a strong scientific direction to our photodynamic therapy program.
On the Company's Clinical Advisory Board (CAB), I have Dr. Christopher Nicodemus, a clinical expert in tumor immunology and drug development who has been championing the combinatorial immunotherapeutic approach supported by numerous publications and patents. He relies on the advice of his fellow CAB members, key opinion leaders such as Professor William McGuire in the U.S, Professor Ignace Vergote in Belgium and Dr. Thomas Ehlen in Canada.
All members of the CAB have a keen interest in innovative improvements in the area of ovarian cancer and see a great opportunity to advance the previous learning with Oregovomab in the context of combination therapies that will better access the immune response and limit immune suppression that has impeded earlier efforts to vaccinate against cancer.
Q: Investorideas.com
Can you share with readers the significance of some of your key relationships including Stanford University and UCLA?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Significance of Key Relationships:
We are very pleased to be licensing IgE technologies developed by the distinguished scientists from these prestigious institutions. In addition, we are also working closely with the Eppley Cancer Institute at the University of Nebraska to develop animal models and complete pre-clinical testing of potential drug candidates.
Q: Investorideas.com
With all biotech companies, funding is a key factor to success; last November you announced a $1million placement for Quest PharmaTech. C an you explain the significance of this round of financing and where this takes you to?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
We wanted to strengthen our relationship with our long term investment partner, AD Biotech Co., Ltd. AD Biotech has committed $12 Million to fund our ongoing clinical programs during the next two years. We were pleased with their confidence in Quest as demonstrated by their investment of $1 Million at a premium share price.
Q: Investorideas.com
In closing what are some of the key milestones for 2014 for Quest PharmaTech?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Some of the key 2014 milestones we hope to achieve in the coming year include completing patient enrollment of the Oregovomab clinical trial and obtaining preliminary data for the Oregovomab clinical trial in Italy and US; initiating a clinical study combining Oregovomab with immuno-adjuvants; expanding the Company's opportunities for revenue generation through product sales of some evidence based over-the-counter nutraceutical and cosmetic products licensed from our joint venture partner; generating critical additional data demonstrating the therapeutic potential of our proprietary IgE portfolio; and, pursuing out-licensing arrangements as a source of additional revenue and validation for our technologies.
About Quest PharmaTech Inc.:
Quest PharmaTech Inc. (Quest) is a publicly traded (TSX Venture), Alberta-based biotechnology company committed to the development and commercialization of oncology product candidates. It is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds, and monoclonal antibodies that target certain tumor antigens that are presented in a variety of cancers. Quest believes that by combining these antibodies with other cancer therapies such as chemotherapy or photodynamic therapy, it can potentially further complement and enhance treatment outcomes compared to antibody treatment alone. http://www.questpharmatech.com/
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy and Latin American stocks.
Sign up for our free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: QPT.V, a public company, has engaged Investorideas.com for public relations services for four thousand a month retainer fee.
More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com

Biopharma Q&A Interview; Dr. Steve N. Slilaty Ph.D., Chairman, CEO of Sunshine Biopharma (OTCQB: SBFM) Shares Insight into Recent Company Move and Updates Lead Cancer Compound Adva-27a

New York, NY, Point Roberts, WA - December 19, 2013 (Investorideas.com Biotech Newswire) Investorideas.com, a research and news portal covering leading sectors, issues an exclusive Q&A interview with Dr. Steve N. Slilaty Ph.D., Chairman and CEO of Sunshine Biopharma Inc. (OTCQB: SBFM). Sunshine is Biopharma a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.

Dr. Steve N. Slilaty shares insight to the recent news that it has re-domiciled in Canada for expansion through acquisitions and to gain access to various financing opportunities available to Canadian corporations, in addition to updating the current status of its lead cancer product Adva-27a.
Q: Investorideas.com
Dr. Slilaty can you explain to investors the significance of the recent move to Canada corporately and what direct benefits are realized?
A: Dr. Steve N. Slilaty Ph.D., Chairman, CEO
There are several advantages relating to the fiscal environment in Canada which are conducive to companies planning to expand through acquisitions. For example, there are provisions in the Canadian Tax Act which allow Canadian companies to acquire other Canadian companies in a share exchange transaction on a tax exempt basis. In addition, there are significant tax credits available to Canadian companies conducting R&D in Canada and Sunshine’s drug development program would benefit a great deal such tax provisions.
Q: Investorideas.com
For investors unfamiliar with your company, can you give a brief history of some of the data and testing on your lead compound Adva-27a and the basic principle of how it works?
A: Dr. Steve N. Slilaty Ph.D., Chairman, CEO
Adva-27a is Topoisomerase 2 inhibitor. Suppression of Topoisomerase 2 enzyme activity is a well-established anticancer target. Unlike all existing Topoisomerase 2 inhibitors, Adva-27a continues to work even when cells become multidrug resistant. This remarkable property is unique to Adva-27a! Our preclinical studies to date have shown that:

• Adva-27a is effective at killing different types of multidrug resistant cancer cells, including:
• Breast Cancer Cells (MCF-7/MDR)
• Small-Cell Lung Cancer Cells (H69AR)
• Uterine Cancer (MES-SA/Dx5)
• Pancreatic Cancer (Panc-1)
• Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs
• Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats
• Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates
• Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar
• Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats
• Adva-27a does not inhibit tubulin assembly
• Adva-27a exhibits low toxicity levels as indicated by measurements using the non-cancerous cell line, HMEC

Q: Investorideas.com
With data on multiple cancers, is there one area the company will focus on specifically?
A: Dr. Steve N. Slilaty Ph.D., Chairman, CEO
Yes, we are initially focused on treating breast cancer patients whose disease has become multidrug resistant. These patients currently have no treatment options available to them as all existing anticancer drugs cease to work. We are anxious to make our Adva-27a available to them soon. To this end, we have signed an agreement with McGill University’s Jewish General Hospital here in Montreal ( Canada) to conduct Phase I clinical trials on such patients. This is the first step in our clinical development program of Adva-27a.
Q: Investorideas.com
For investors unfamiliar with the difference between getting approval in Canada vs. US FDA approval, can you explain the process in Canada, the timelines, cost and what is next for Sunshine Biopharma?
A: Dr. Steve N. Slilaty Ph.D., Chairman, CEO
The approval process in Canada is very similar to that of the United States. Health Canada has very similar guidelines to those established by the FDA in the U.S. In fact, our Phase I clinical trials protocols are compliant with the requirements on both sides of the boarder and we will be able to file our results both in Canada and the US pretty much simultaneously. In terms of timelines, like the U.S., Canada has a so-called “fast-track” process for which is available for drugs that treat terminally ill patients as is the case with Adva-27a. Next, we anticipate initiating the human trials following completion of our next round of financing.
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.
About Sunshine Biopharma Inc. (OTCQB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer www.sunshinebiopharma.com
Recent news: http://finance.yahoo.com/news/sunshine-biopharma-domicile-canada-expansion-130000999.html
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for our free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and use our online stock directories to research stocks - waters stocks, renewable energy, tech, mobile, mining stocks and more… http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM compensates Investorideas for news publication and distribution (one hundred thousand 144 shares in lieu of cash for a six month period) more disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 -   Source - www.Investorideas.com

Solar Stock XsunX (OTCQB: XSNX) to Deliver Several New Commercial Solar Systems

ALISO VIEJO, CA - December 19, 2013 (Investorideas.com renewable energy newswire) XsunX, Inc. (OTCQB: XSNX), a renewable energy technology, systems, and services company, today announced the successful sale of an additional 20kW commercial solar system in Southern California. This comes on the heels of 50kW of solar systems projects announced earlier this week.

"We are pleased with the sales results we announced this week, but we are even more pleased with the response to our media marketing campaign that was launched last week targeting major Southern California communities from Ventura to San Diego," stated XsunX CEO, Tom Djokovich.
Southern California represents one of the largest commercial PV system markets in the nation and a tremendous opportunity for the Company. Mr. Djokovich continued, "We are finding that business owners with large facilities and large electric bills are contacting us to see how XsunX can help them. We are just now starting to get our message out and the response has been very good. Our focus is on providing reliable services to these businesses."
The Company has specifically targeted the commercial and industrial PV installations market for several reasons. While the sales cycle can be more complex and lengthy, the projects offer XsunX the ability to generate system sales approaching 1 megawatt or more and potentially millions of dollars in contract value. In addition, commercial PV systems offer clients the largest cash benefits, and return on investment.
To help secure sales, the Company can now offer system financing to its customers. "Our goal was to make buying a commercial PV system as easy for our clients as buying a car," offered Mr. Djokovich. "We recently qualified to offer up to $1 million of project funding which completes our ability to offer the best project financial analysis, PV systems design and technologies, and zero down low interest financing."
About XsunX
XsunX focuses on providing solar energy solutions that provide the greatest bottom-line financial benefits. The Company's background and experience spans virtually all aspects of solar including technology assessment, design, and development. We have a deep passion for solar and have worked to pioneer new technologies and solar business solutions focused at making solar an affordable energy option. For more information, please visit the Company's website at www.xsunx.com.
Safe Harbor Statement
Matters discussed in this release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein, are included in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contact:
Tom Djokovich
President and CEO
949-330-8060
info@xsunx.com
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by XSNX for news distribution averaging 1500 per month. http://www.investorideas.com/About/Disclaimer.asp

Biometric Stock Alert: NXT-ID, Inc. (OTCQB: NXTD) Appoints Two Former MasterCard Executives to Its Newly Formed Advisory Board

SHELTON, CT - December 17, 2013 (Investorideas.com Newswire) NXT-ID (OTCQB: NXTD), a biometrics company focused on the growing m-commerce market, announces the appointment of two key advisory board members, Mr. Lawrence Flanagan and Mr. Ken Moy. The appointments from the card payment industry align with the company's roll-out and 2014 launch of The Wocket™, a next generation biometrically secure wallet.

"We are honored and excited to have two luminaries of the card payment world on our advisory board," said Gino Pereira, CEO of NXT-ID, Inc. "Their experience is invaluable to our future prospects and growth for The Wocket™. We look forward to growing our advisory board over the next few months with equally talented and experienced individuals."
Mr. Lawrence Flanagan is President and Founder of New Tech Haven since January 2013 and was formerly the Executive Dean at the University of New Haven College of Business. Flanagan is regarded as one of the most accomplished global marketing leaders in the country. Prior to his career in academia, he spent nearly three decades in corporate America as an executive at MasterCard Worldwide, the Procter & Gamble Company and L'Oreal USA.
As the global chief marketing officer at MasterCard, he managed a $1.5 billion budget, directed marketing strategies in more than 50 countries and helped launch the company's hugely successful "Priceless" advertising campaign. He also established strategic partnerships with Major League Baseball, the PGA Tour and Champions League soccer in Europe and was part of the executive team that spearheaded MasterCard's highly successful initial public offering in 2006. He earned six Gold Effie awards from the American Marketing Association, the most prestigious honor among marketing professionals, and was recognized as one of the "25 Most Influential People in Sports" in 2004 by SportBusiness International. In 2008, the NY AdClub named Flanagan "Person of the Year". In 2013, the University of New Haven awarded a Doctor of Business Administration honoris causa to Flanagan.
Flanagan, who is a former national co-chair of the CMO Collective, is active with Save the Children and previously served on the University of New Haven's Board of Governors. He is on the advisory boards of Visitdays.com and Fraud.net.
The second appointment, Mr. Ken Moy, was formerly senior vice president and Group Head of US Emerging Payments at MasterCard Worldwide.
Moy led the execution of the company's digital conversion strategy and managed all aspects of product development and a diverse set of existing products including online and offline payments, authentication solutions, spending controls and alerts services. He launched MasterPass, the firm's digital wallet solution and important pillar to overall strategy, achieving over 25,000 online merchants, and wallet distribution with over 20 financial institutions.
Moy has extensive experience in large-scale rollouts, partnerships, corporate development, strategic planning, business administration and product management, in the technology, commerce and financial services space. He led an exclusive agreement with Google, Citibank and First Data to launch Google Wallet, the first commercially available mobile payment solutions. He also led an exclusive agreement with Intel for access to embedded technology in Intel PCs to deliver enhanced security and user experience for electronic ecommerce.
Prior to his nearly 14 year career at MasterCard, Mr. Moy enjoyed a successful 10 year career at Citibank where he held a range of leadership roles in the firm's payment cards and wholesale banking businesses.
He was a Smart Card Alliance Board Member from 2004-2010 and is a frequent industry speaker and commentator.
Presently, Moy is Founder and President of Harvest Advisors LLC, a provider of strategy, business development and implementation advice to start-ups and technology solution providers in the developing commerce space.
NXT-ID, Inc. released the first images of The Wocket™ on its corporate website and product website late last week.
About The Wocket™
The Wocket™ is a next generation designed to replace all the cards in your wallet without draining your cell phone's battery; no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://thewocket.com/
About NXT-ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms. NXT-ID's wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification and has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013 :Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous services
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Q&A Interview with CEO of Tekcapital; Open Innovation Network Enables Companies to Research and Acquire Game Changing Technology

New York, NY, Point Roberts, WA - December 13, 2013 (www.investorideas.com newswire) Investorideas.com issues an exclusive interview with Mr. Clifford M. Gross, Ph.D., Chief Executive Officer of Tekcapital. Dr. Gross shares insight into his company’s discovery search engine which identifies intellectual properties from 3300 plus universities and how they are enabling companies to gain market leadership over their competition with access to next- generation technology.

Q: Investorideas.com
Can you give a brief background on the history of the Company and how the database and network were developed?
A: Clifford M. Gross, Ph.D., Chief Executive Officer
Tekcapital was established by a team of Oxford University, Said business school graduates in June 2012. The problem that we sought to solve was how to help companies profit from new university-developed technologies and intellectual properties. As the pace of innovation has dramatically accelerated firms of all sizes have found it more difficult to remain competitive technologically by relying on in-house developed innovations and intellectual properties. Globally, universities produce roughly 100,000 new patents each year, yet 80% of these discoveries fail to be used commercially. We realized that this was in part due to market inefficiency. To address this we developed a market driven, turn-key solution to make it easy for companies to find, review and acquire the intellectual properties they need to improve and protect their products. The unique service we have developed incorporates global discovery search, objective scientific review of technologies and industry leading university to business transaction experience to help secure the deal.
The first step was to make the global university supplier network easily accessible. We achieved this by developing a new search engine that directly reaches into the technology commercialization offices of the world's leading research institutions. Currently, there are approximately 15,000 research institutions spread out over 160 countries. The top 3,300 of these institutions produce roughly 80% of the world's peer-reviewed, university-based, published scientific research. We believe, as do many of clients, that these institutions are the engine room for global technology development. So now, for the first time, we have made it easy for clients to find new developments available in any field of science, technology or medicine. Finding these technologies is just the first step. We provide actionable information for our clients, which mean technologies that fit our clients' needs and where the science has been vetted and verified by a subject matter expert. For this process we developed a science advisory council that could in real-time, objectively evaluate new intellectual properties for our clients. The final and most important step was to build a team that had significant technology acquisition experience. Our management team, collectively have closed more than 400 transactions from universities to businesses of all sizes.
Q: Investorideas.com
Can you give us some examples of the types of clients you assist and what sectors they are in?
A: Clifford M. Gross, Ph.D., Chief Executive Officer
Clients' usually engage us for one of two reasons. Either they are seeking to enhance their pipeline of intellectual properties to improve their innovation capabilities or they have identified a weakness in their intellectual property portfolio that they want to fill, to better protect their intellectual property. Clients range in size from early-stage firms to multi-nationals. Their sectors cover, new materials, medical devices, drugs, diagnostics, electronics, software, cloud computing, consumer products, energy and nutraceuticals.
Q: Investorideas.com
We are seeing technology advance faster than we could have imagined at this time in history. We have witnessed a lot of big companies disappear like dinosaurs because they didn't see what was coming next. Can you give us some insight as to what you are seeing first hand at the university level and how tapping into this rapid technology development can really impact the next phase of growth for companies?
A: Clifford M. Gross, Ph.D., Chief Executive Officer
Like individuals, companies have life spans. What's interesting is unlike individuals, the life-span of companies is becoming shorter as a result of the quickening pace of innovation. With the development and wide spread use of social networks, smart phones and tablets the innovation pace is continuing to accelerate. It's pretty easy to miss not only the next big development but perhaps the next five big developments in your space; primarily because they are not occurring inside of your organization and are not under your control. The net effect is technological obsolescence or market irrelevance. In our opinion, no amount of capital or historic brand luster can neutralize these corporate risks without the right strategy. We have re-imagined R&D primarily an external function, augmented by in-house development and marketing. For many companies this is a difficult concept to embrace as it requires the ability to relinquish the illusion of control over the technology development trajectory and tolerate the ambiguity of external innovation based on the fact that the majority of the world's finest minds reside outside of your organization. Once a firm understands and accept this concept, addressing the need for continuous innovation becomes a lot more manageable.
Q: Investorideas.com
For companies interested in your services can you give a brief explanation of how the relationship with Tekcapital, the university and the client works?
A: Clifford M. Gross, Ph.D., Chief Executive Officer
It's very straight forward. We are engaged under a retained relationship by our clients and we receive success fees upon closing transactions. For the universities of the world we are a no-cost channel partner that results in increased review and acquisition of their intellectual properties.
Q: Investorideas.com
Your Company has attracted an impressive executive management team: can you tell our readers the common vision that brought the team together?
A: Clifford M. Gross, Ph.D., Chief Executive Officer
We believe a company will never be better than the team that drives it forwards. As a team we are passionate about creating marketplace value from university intellectual property for our clients and seeing new innovations enter the market that can improve the quality of life.
About Tekcapital, Ltd. - The World's Largest University Network for Open Innovation
Tekcapital helps clients profit from new, university-developed intellectual properties. With our proprietary discovery search engine, linked to 3,300+ universities in 160 countries, coupled with expert scientific review, we provide a turn-key service to make it easy for clients to find and acquire the IP they need to create a competitive advantage. www.tekcapital.com
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy and Latin American stocks.
Follow Investorideas.com on Twitter   http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for our free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Tekcapital, a private company, has engaged Investorideas.com for public relations services.
More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country.
800-665-0411 -   Source - www.Investorideas.com